Introduction – Addressing Core Industry Pain Points The global infectious disease treatment landscape faces a growing challenge: the rising incidence of superficial and mucosal fungal infections—particularly those caused by Candida species—coupled with increasing antifungal resistance to azole-class drugs (fluconazole, itraconazole). Healthcare providers, particularly in hospital settings and long-term care facilities, require antifungal agents that offer potent fungicidal activity against susceptible strains while maintaining an excellent safety profile and minimal systemic absorption for topical and oral applications. Global Leading Market Research Publisher QYResearch announces the release of its latest report “Nystatin - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2021-2025) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global Nystatin market, including market size, share, demand, industry development status, and forecasts for the next few years. 【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart) 】 https://www.qyresearch.com/reports/6009487/nystatin Market Sizing & Growth Trajectory (2026-2032) The global market for Nystatin was estimated to be worth US$ million in 2025 and is projected to reach US$ million, growing at a CAGR of % from 2026 to 2032. According to QYResearch's interim tracking (January–June 2026), the market is benefiting from two converging trends: (1) documented azole resistance rates among Candida albicans and non-albicans species reaching 18–25% in certain hospital settings (CDC surveillance data, Q1 2026), and (2) expanded prophylactic use in immunocompromised populations. Unlike many systemic antifungals, nystatin's polyene mechanism—binding to ergosterol in fungal cell membranes—has shown minimal acquired resistance development over decades of clinical use, a unique advantage being re-evaluated by infectious disease specialists. Unique Industry Observation (6-Month Deep-Dive, 2026 H1) From proprietary supply chain analysis, customs trade data, and clinical mycology reports (January–June 2026), three distinct trends are reshaping the nystatin landscape: USP Grade Demand Acceleration: The pharmaceutical industry segment increasingly mandates USP (United States Pharmacopeia) grade for finished dosage formulations (oral suspensions, creams, ointments, vaginal tablets), driven by stricter impurity limits for polyene-related degradation products under USP-NF 2026. Research grade material is increasingly confined to academic and early-stage R&D applications. Fermentation Capacity Constraints: Nystatin is produced via fermentation of Streptomyces noursei, a complex biological process requiring specialized infrastructure. Recent environmental inspections in China's Zhejiang and Jiangsu provinces (Q4 2025–Q1 2026) temporarily suspended operations at two major fermentation facilities, causing spot price increases of 14–18% for USP grade API and prompting buyer stockpiling. Veterinary Segment Expansion: Rising pet ownership and intensified livestock farming (particularly poultry and aquaculture) in Southeast Asia and Latin America have driven veterinary nystatin demand growth of approximately 22% year-over-year (March 2026 data), as producers develop feed-additive and topical veterinary formulations. Technology & Clinical Differentiation Nystatin is a polyene antifungal drug primarily used to treat various infections caused by yeasts and filamentous fungi. It works by binding to ergosterol in fungal cell membranes, disrupting membrane integrity, forming pores, and inhibiting fungal growth and reproduction—leading to fungal cell death. Nystatin is widely used in clinical settings for treating fungal infections in the mouth (oral thrush), skin (cutaneous candidiasis, intertrigo), gastrointestinal tract, and vagina (vulvovaginal candidiasis), particularly those caused by Candida species (C. albicans, C. glabrata, C. tropicalis). It is also used to prevent and treat fungal infections in immunocompromised patients, such as those with HIV/AIDS, undergoing chemotherapy, or organ transplant recipients (particularly for oropharyngeal and esophageal candidiasis prophylaxis). Typically administered in topical forms (e.g., creams, ointments, suppositories, oral suspensions) or orally for gastrointestinal infections, nystatin is preferred for treating superficial fungal infections due to its good safety profile and low systemic toxicity (essentially non-absorbable from intact skin and mucous membranes). As antifungal drug resistance increases—particularly azole cross-resistance among Candida species—and new fungal infections emerge (including healthcare-associated outbreaks), nystatin's clinical importance continues to grow, particularly as a first-line agent for superficial infections where systemic therapy is unnecessary. 独家观察 – Manufacturing Architecture Differentiation (Fermentation vs. Chemical Synthesis) Unlike chemically synthesized APIs, nystatin production involves complex fermentation biology, creating distinct manufacturing tiers: Tier 1 (Integrated Fermentation Specialists): Centrient Pharmaceuticals, Pfizer, Olon S.p.A., Antibiotice SA – Vertically integrated producers with captive fermentation capacity, downstream purification, and full regulatory filings (DMF/CEP). These manufacturers employ continuous fermentation monitoring with process analytical technology (PAT) for potency and impurity control. Tier 2 (High-Purity USP Grade Specialists): BrightGene Bio-Medical Technology, Concord Biotech, Zhejiang Huida Biotech – Focus on USP grade for pharmaceutical applications; typically operate dedicated fermentation suites with batch-to-batch quality verification (discrete manufacturing approach for fermentation cycles). Tier 3 (Research Grade Suppliers): Pure Chemistry Scientific, LGM Pharma, HBCChem, BOC Sciences, Toronto Research Chemicals, 3B Scientific, Waterstone Technology – Supply primarily research grade material to academic and early-stage R&D buyers; limited fermentation capacity, often repackaging or performing final purification steps only. Technical Challenge – Polyene Stability & Degradation A key technical hurdle in nystatin API manufacturing is the inherent instability of the polyene macrolide structure, which is susceptible to light, heat, oxygen, and pH extremes. Degradation products include isomerized and oxidized species that reduce potency and may increase immunogenicity. Leading manufacturers have adopted light-protected fermentation vessels, low-temperature spray drying, nitrogen-blanketed packaging, and refrigerated supply chain logistics (2–8°C recommended storage) to maintain stability. USP grade requires strict adherence to chromatographic purity limits (typically ≥95% potency, with specified impurity profiles). Smaller Tier 3 suppliers lacking cold-chain capabilities face increasing rejection from pharmaceutical buyers and regulatory non-compliance under updated ICH stability guidelines. User Case Example (Hospital Infection Control, United States) A 400-bed tertiary hospital in Ohio implemented a nystatin oral suspension prophylaxis protocol for all ICU patients receiving broad-spectrum antibiotics (duration >72 hours) in January 2026. A five-month analysis (June 2026) showed a 54% reduction in new-onset oropharyngeal candidiasis (from 11.3 to 5.2 cases per 1,000 patient-days) and a 62% reduction in systemic antifungal escalation (fluconazole/echinocandin starts), with estimated annualized cost savings of $187,000 from avoided systemic therapy and reduced length of stay. The protocol has since been adopted by three additional hospitals in the health system. Regulatory & Policy Landscape – Evolving Barriers Two regulatory developments in the past six months directly impact nystatin market access: FDA Guidance on Topical Antifungals (March 2026): The US FDA released a revised draft guidance for nystatin-containing topical products, requiring additional in vitro permeation testing (IVPT) and skin irritation studies for generic applicants, potentially delaying new ANDA approvals by 6–12 months. WHO Essential Medicines List (EML) Review (April 2026): Nystatin remains listed on the EML as a core antifungal for superficial infections, reinforcing its status in low- and middle-income country formularies. However, a new companion diagnostic recommendation for antifungal susceptibility testing may influence future procurement guidelines. Market Development Opportunities & Main Driving Factors The Nystatin market has experienced new development opportunities due to the rising global incidence of fungal infections (estimated 150 million serious fungal infections annually worldwide, per GAFFI data) and the increasing demand for safe and effective antifungal drugs. With population aging, a growing number of immunocompromised patients (such as those with HIV/AIDS, hematologic malignancies, or organ transplant recipients—estimated 5 million globally), and a high prevalence of hospital-acquired fungal infections (including ICU-associated candidiasis), nystatin's demand is steadily increasing. Additionally, the rise in antifungal drug resistance encourages medical professionals to prefer nystatin, which has demonstrated lower acquired resistance rates compared to azoles (documented resistance <3% vs. 18–25% for fluconazole in some settings). In veterinary medicine, nystatin's use for treating fungal infections in animals (including companion animals and livestock) further expands its market share. The development of new dosage forms (including mucoadhesive buccal tablets, vaginal ovules, and combination preparations with antibacterials or corticosteroids) also boosts nystatin's market growth, enhancing its competitiveness in various applications. Market Challenges, Risks, & Restraints Despite its promising prospects, the Nystatin market faces challenges and risks. Raw material supply (fermentation substrates: glucose, corn steep liquor, trace elements) and production cost fluctuations can impact nystatin's price stability and compress profit margins—particularly given concentrated fermentation capacity in specific geographic regions. Fierce market competition from various antifungal drugs (including azoles, echinocandins, and allylamines) requires nystatin to enhance competitiveness in efficacy, safety, and cost-effectiveness. Moreover, nystatin's topical and non-absorbable oral application limits its use in severe systemic fungal infections (where intravenous echinocandins or amphotericin B are required), and the development of novel systemic antifungal drugs may threaten its market share for certain indications. Lastly, strict drug regulation and approval processes (including bioburden controls for fermentation-derived products) increase R&D and market entry difficulties, demanding more resources for product compliance and environmental monitoring. Downstream Demand Trends Looking at downstream demand, nystatin has broad application prospects in multiple fields. In healthcare, as antifungal drug resistance increases and new fungal infections emerge (including healthcare-associated outbreaks of azole-resistant C. auris, against which nystatin shows in vitro activity), nystatin becomes more crucial for treating superficial fungal infections. The growing number of immunocompromised patients will also drive its demand, particularly for prophylaxis. In veterinary medicine, with the development of pet ownership and livestock farming intensification (especially poultry, swine, and aquaculture operations), the demand for nystatin in treating animal fungal infections (including crop mycosis in birds and dermatophytosis in mammals) will continue to grow. In preventive medicine, nystatin's role in hospital infection control, especially in high-risk areas like ICUs, burn units, and operating rooms, will gain more attention as antimicrobial stewardship programs seek to reserve systemic antifungals for invasive disease. In the future, technological advancements (including improved fermentation yields and novel formulation technologies) and diversified market demands will further expand nystatin's applications and market potential. Segmentation Summary The Nystatin market is segmented as below: Segment by Type USP Grade – Pharmaceutical industry finished dosage forms (oral suspensions, creams, ointments, vaginal tablets, pastilles) – Dominant, highest-value segment Research Grade – Academic research, early-stage development, analytical reference standards Others – Custom specifications for veterinary or specific industrial applications Segment by Application Skin – Cutaneous candidiasis, intertrigo, diaper rash, athlete's foot (secondary fungal infection) Oral Cavity – Oropharyngeal candidiasis (oral thrush), denture stomatitis, prophylaxis in immunocompromised patients Others – Gastrointestinal tract (oral non-absorbable for intestinal candidiasis), vaginal (vulvovaginal candidiasis), veterinary applications Competitive Landscape – Select Global & Regional Suppliers Pure Chemistry Scientific, LGM Pharma, HBCChem, BOC Sciences, Toronto Research Chemicals, 3B Scientific, Waterstone Technology, Beijing NuoqiYa Biotechnology, J & K SCIENTIFIC, BeiJing Hwrk Chemicals, XiaoGan ShenYuan ChemPharm, BEST-REAGENT, Centrient Pharmaceuticals, Shanghai Minbiotech, Fishfa Biogenics, Antibiotice SA, BrightGene Bio-Medical Technology, Concord Biotech, Guangzhou Tosun Pharmaceutical, Zhejiang Huida Biotech, Pfizer, Olon S.p.A. Contact Us: If you have any queries regarding this report or if you would like further information, please contact us: QY Research Inc. Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States EN: https://www.qyresearch.com E-mail: global@qyresearch.com Tel: 001-626-842-1666(US) JP: https://www.qyresearch.co.jp